Nichols & Pratt Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nichols & Pratt Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$313K	Hold	1,039	–	–	0.02%	91
2026 Q1	$344K	Hold	1,039	–	–	0.02%	89
2025 Q4	$413K	Sell	1,039 -4	-0.4%	-$1.77K	0.03%	83
2025 Q3	$476K	Hold	1,043	–	–	0.03%	82
2025 Q2	$340K	Hold	1,043	–	–	0.02%	89
2025 Q1	$282K	Sell	1,043 -332	-24%	-$85.3K	0.02%	87
2024 Q4	$324K	Hold	1,375	–	–	0.02%	86
2024 Q3	$378K	Buy	+1,375	New	+$358K	0.02%	87

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nichols & Pratt Advisers's ALNY Position: Q2 2026 in Review

Nichols & Pratt Advisers held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 1,039 shares worth $313K. The position accounts for 0.02% of the portfolio, ranked #91.

Nichols & Pratt Advisers first reported a position in ALNY in Q3 2024 and has held it in 8 quarters since. The position peaked at $476K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Nichols & Pratt Advisers held 1,039 shares of Alnylam Pharmaceuticals worth $313K as of Q2 2026.
Nichols & Pratt Advisers left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up 0.02% of Nichols & Pratt Advisers's portfolio in Q2 2026, its #91 holding.
Nichols & Pratt Advisers first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Nichols & Pratt Advisers's Alnylam Pharmaceuticals position peaked at $476K in Q3 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Nichols & Pratt Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.